Nutritional And Metabolic Diseases clinical trials

Explore recruiting nutritional and metabolic diseases clinical trials.

Recruiting nutritional and metabolic diseases studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Nutritional And Metabolic Diseases trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, double-blind, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with recently diagnosed Stage 3 Type 1 Diabetes (T1D) (βETA PRESERVE)

Czechia, Netherlands, Italy, Germany, Belgium, France +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of SYNB1934 in Patients with PKU (SYNPHENY-3)

Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

The Chronic kidney disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE)

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

LONG-TERM INTERVENTIONAL FOLLOW-UP STUDY UP TO 4 YEARS OF AGE OF CHILDREN WITH PRADER-WILLI SYNDROME INCLUDED IN THE OTBB3 CLINICAL TRIAL AND COMPARISON WITH AN UNTREATED COHORT OF CHILDREN WITH PRADER-WILLI SYNDROME (OTBB3 FOLLOW-UP)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A PHASE I, OPEN-LABEL, RANDOMIZED, ADAPTIVE, CROSS-OVER STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF NIZUBAGLUSTAT CAPSULES COMPARED TO ORALLY DISPERSIBLE TABLETS AND THE FOOD EFFECT IN HEALTHY VOLUNTEERS

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

Nutritional And Metabolic Diseases trials by city

Nutritional And Metabolic Diseases clinical trials

Recruiting nutritional and metabolic diseases studies right now

Bariatric Surgery and Modulation of Perceived Satiety

ENDOPLY System in Humans: a Pilot Study

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Impact of Microbiome-changing Interventions on Food Decision-making

Physical Activity Targeting Metabolic Syndrome for Prevention of Breast Cancer in SAI Women

Leveraging Community-clinical Linkages to Address Unmet Social Needs for People With Diabetes

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Time-Restricted Eating After Bariatric Surgery

U.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures

Feasibility and Adherence to a Technology-assisted Home-based Strength Training Program in Adults With Type 2 Diabetes Mellitus and Mild Cognitive Impairment

Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

Also recruiting in Europe

A randomized, double-blind, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with recently diagnosed Stage 3 Type 1 Diabetes (T1D) (βETA PRESERVE)

A Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of SYNB1934 in Patients with PKU (SYNPHENY-3)

The Chronic kidney disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE)

LONG-TERM INTERVENTIONAL FOLLOW-UP STUDY UP TO 4 YEARS OF AGE OF CHILDREN WITH PRADER-WILLI SYNDROME INCLUDED IN THE OTBB3 CLINICAL TRIAL AND COMPARISON WITH AN UNTREATED COHORT OF CHILDREN WITH PRADER-WILLI SYNDROME (OTBB3 FOLLOW-UP)

Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.

A PHASE I, OPEN-LABEL, RANDOMIZED, ADAPTIVE, CROSS-OVER STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF NIZUBAGLUSTAT CAPSULES COMPARED TO ORALLY DISPERSIBLE TABLETS AND THE FOOD EFFECT IN HEALTHY VOLUNTEERS

Nutritional And Metabolic Diseases trials by city

Other conditions